>On a related note, SRDX has said they might secure a partner for funding the phase 2 with triamcinolone. This surprised me, because I worry that such a partnership could leverage SRDX into an exclusive license for the delivery platform. Perhaps giving an exclusive is simply the reality of the climate. Thoughts on this?<
If a partner pays for the phase-2 I-vation program, they will probably get an exclusive license on the platform or at worst a co-exclusive license such as the one ANPI has with BSX and Cook. Whether this is a good idea or a bad idea for SRDX depends on the details, but it is IMO probably a bad idea motivated by investors’ preoccupation with short-term EPS.
Market Data 
Markets 
AI
